SAN FRANCISCO, October 13, 2015 /PRNewswire/ --
Keystone Heart, a medical device company and the developer of CE marked TriGuard™ Cerebral Protection Device, announced that it will be sharing additional findings from the multicenter Neuro-TAVR study with the clinical community at the Trans-Catheter Therapeutics (TCT) meeting in San Francisco this week.
Help employers find you! Check out all the jobs and post your resume.
